MX2023003258A - Tratamiento de enfermedades mediadas por nf-kb. - Google Patents
Tratamiento de enfermedades mediadas por nf-kb.Info
- Publication number
- MX2023003258A MX2023003258A MX2023003258A MX2023003258A MX2023003258A MX 2023003258 A MX2023003258 A MX 2023003258A MX 2023003258 A MX2023003258 A MX 2023003258A MX 2023003258 A MX2023003258 A MX 2023003258A MX 2023003258 A MX2023003258 A MX 2023003258A
- Authority
- MX
- Mexico
- Prior art keywords
- îob
- treatment
- mediated disease
- human patient
- vamorolone
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- ZYTXTXAMMDTYDQ-DGEXFFLYSA-N vamorolone Chemical compound C([C@H]12)CC3=CC(=O)C=C[C@]3(C)C1=CC[C@@]1(C)[C@H]2C[C@@H](C)[C@]1(O)C(=O)CO ZYTXTXAMMDTYDQ-DGEXFFLYSA-N 0.000 abstract 1
- 229950011597 vamorolone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación provee métodos de tratamiento o de reducción de los síntomas de la distrofia muscular en un paciente humano de entre 1 día y 18 años de edad, que comprenden administrar, al paciente humano en necesidad de ello, una cantidad terapéuticamente efectiva de vamorolona y/o de una sal de la misma.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063081073P | 2020-09-21 | 2020-09-21 | |
| US202163195473P | 2021-06-01 | 2021-06-01 | |
| US202163214908P | 2021-06-25 | 2021-06-25 | |
| PCT/US2021/051274 WO2022061287A1 (en) | 2020-09-21 | 2021-09-21 | TREATMENT OF NF-κB-MEDIATED DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003258A true MX2023003258A (es) | 2023-05-08 |
Family
ID=80776432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003258A MX2023003258A (es) | 2020-09-21 | 2021-09-21 | Tratamiento de enfermedades mediadas por nf-kb. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220184098A1 (es) |
| EP (1) | EP4213855A4 (es) |
| JP (1) | JP2023543439A (es) |
| KR (1) | KR20230092905A (es) |
| AU (1) | AU2021343534A1 (es) |
| CA (1) | CA3170698A1 (es) |
| IL (1) | IL301500A (es) |
| MX (1) | MX2023003258A (es) |
| WO (1) | WO2022061287A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4436583A4 (en) * | 2021-11-22 | 2025-04-02 | ReveraGen BioPharma, Inc. | TREATMENT OF NF-kB-MEDIATED DISEASE |
| WO2025199347A1 (en) * | 2024-03-21 | 2025-09-25 | Reveragen Biopharma, Inc. | Treatment of glomerulonephritis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007022427A2 (en) * | 2005-08-18 | 2007-02-22 | Accelalox, Inc. | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway |
| US10464967B2 (en) * | 2011-11-29 | 2019-11-05 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
| WO2014205045A1 (en) * | 2013-06-18 | 2014-12-24 | Downes, Michael | Methods of treating muscular dystrophy |
| IL316145A (en) * | 2015-09-08 | 2024-12-01 | Childrens Hospital Philadelphia | Methods for diagnosing and treating anxiety disorder |
| US11382922B2 (en) * | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
-
2021
- 2021-09-21 JP JP2023518416A patent/JP2023543439A/ja active Pending
- 2021-09-21 EP EP21870412.0A patent/EP4213855A4/en active Pending
- 2021-09-21 KR KR1020237013258A patent/KR20230092905A/ko active Pending
- 2021-09-21 IL IL301500A patent/IL301500A/en unknown
- 2021-09-21 AU AU2021343534A patent/AU2021343534A1/en active Pending
- 2021-09-21 MX MX2023003258A patent/MX2023003258A/es unknown
- 2021-09-21 WO PCT/US2021/051274 patent/WO2022061287A1/en not_active Ceased
- 2021-09-21 CA CA3170698A patent/CA3170698A1/en active Pending
-
2022
- 2022-02-21 US US17/651,879 patent/US20220184098A1/en not_active Abandoned
-
2023
- 2023-08-14 US US18/449,312 patent/US20240139210A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4213855A4 (en) | 2024-10-23 |
| CA3170698A1 (en) | 2022-03-24 |
| IL301500A (en) | 2023-05-01 |
| WO2022061287A1 (en) | 2022-03-24 |
| JP2023543439A (ja) | 2023-10-16 |
| KR20230092905A (ko) | 2023-06-26 |
| US20240139210A1 (en) | 2024-05-02 |
| EP4213855A1 (en) | 2023-07-26 |
| AU2021343534A1 (en) | 2023-05-11 |
| US20220184098A1 (en) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| NZ591362A (en) | Multiple-variable dose regimen for treating tnfa-related disorders | |
| MX2024008350A (es) | Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla. | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| MX2023001140A (es) | Uso del dexpramipexol para el tratamiento de asma moderado a grave. | |
| MX2024011142A (es) | Tratamiento de neurofibromas cutaneos con mirdametinib. | |
| SE0400184D0 (sv) | New therapeutical use | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| MX2022001287A (es) | Composiciones y metodos de uso de celulas madre multipotentes para reducir la enfermedad y mejorar el bienestar. | |
| CA2899234C (en) | Method of treating fibrosis in skeletal muscle tissue | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| PL1732551T3 (pl) | Perheksylina do leczenia przewlekłej niewydolności serca | |
| MX2023006720A (es) | Tratamiento con ciclobenzaprina para fibromialgia. | |
| EP4527454A3 (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. | |
| WO2008088987B1 (en) | Treatment of pain with naloxone | |
| IL318374A (en) | Methods of administering nalbuphine | |
| BR112023023702A2 (pt) | Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga | |
| Akshaya et al. | Effect of Dry Needling on Patients with Lumbar Radiculopathy in Reducing Pain and Increasing Range of Motion Compared to Interferential Therapy. | |
| Dakova | Physical therapy for head and neck cancer patients | |
| Liu et al. | Clinical observation of a combination of acupuncture and drug administration for non-specific acute lumbar sprain | |
| ATE495750T1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten | |
| MX2024002602A (es) | Métodos para prevenir y tratar el dolor y síntomas asociados. | |
| WO2024253833A3 (en) | Methods for treating dermatomyositis with brepocitinib |